Boston Common Asset Management LLC Has $5.26 Million Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Boston Common Asset Management LLC raised its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.1% in the 4th quarter, HoldingsChannel reports. The fund owned 49,752 shares of the medical equipment provider’s stock after purchasing an additional 528 shares during the period. Boston Common Asset Management LLC’s holdings in Zimmer Biomet were worth $5,255,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Dunhill Financial LLC increased its position in shares of Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 218 shares during the period. Ashton Thomas Securities LLC acquired a new stake in Zimmer Biomet during the third quarter worth $28,000. Bangor Savings Bank bought a new stake in Zimmer Biomet in the 3rd quarter valued at $31,000. Brooklyn Investment Group acquired a new position in shares of Zimmer Biomet in the 3rd quarter valued at $35,000. Finally, Quarry LP acquired a new stake in shares of Zimmer Biomet during the 2nd quarter valued at about $53,000. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Shares of ZBH stock opened at $109.65 on Friday. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. The firm has a market capitalization of $21.83 billion, a price-to-earnings ratio of 20.85, a PEG ratio of 1.79 and a beta of 1.02. The firm’s 50 day moving average is $107.81 and its 200-day moving average is $107.97. Zimmer Biomet Holdings, Inc. has a 1 year low of $100.67 and a 1 year high of $133.90.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.74. The firm had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The business’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.65 EPS. Sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Monday, December 30th will be given a $0.24 dividend. The ex-dividend date of this dividend is Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.88%. Zimmer Biomet’s payout ratio is 18.25%.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. JPMorgan Chase & Co. raised shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $125.00 to $128.00 in a research report on Tuesday, December 17th. Evercore ISI dropped their target price on Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating for the company in a report on Tuesday, October 1st. Truist Financial raised their target price on Zimmer Biomet from $117.00 to $118.00 and gave the stock a “hold” rating in a research report on Wednesday, December 18th. BTIG Research lowered their price target on Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating on the stock in a research report on Thursday, October 3rd. Finally, Oppenheimer cut their price objective on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a report on Tuesday, October 15th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus price target of $123.33.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.